1、 LU W, JIN X L, YANG C, et al. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: a single-center randomized controlled trial[J]. Cancer Biol Ther, 2017, 18(6):433. LU W, JIN X L, YANG C, et al. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: a single-center randomized controlled trial[J]. Cancer Biol Ther, 2017, 18(6):433.
2、 ZHANG H. Apatinib for molecular targeted therapy in tumor[J]. Drug Des Devel Ther, 2015, 9(11):6075-6081. ZHANG H. Apatinib for molecular targeted therapy in tumor[J]. Drug Des Devel Ther, 2015, 9(11):6075-6081.
3、 管清龙,纪卫政,任伟新,等.肝癌介入治疗后血清缺氧诱导因子和血管内皮生长因子含量变化对预后的影响[J]. 介入放射学杂志,2014,23(02):142-146. 管清龙,纪卫政,任伟新,等.肝癌介入治疗后血清缺氧诱导因子和血管内皮生长因子含量变化对预后的影响[J]. 介入放射学杂志,2014,23(02):142-146.
4、 KOCH S, TUGUES S, LI X, et al. Signal transduction by vascular endothelial growth factor receptors[J]. Biochem J, 2011, 437(2):169-183. KOCH S, TUGUES S, LI X, et al. Signal transduction by vascular endothelial growth factor receptors[J]. Biochem J, 2011, 437(2):169-183.
5、 JIA Z Z, JIANG G M, FENG Y L. Serum HIF-1alpha and VEGF levels pre-and post-TACE in patients with primary liver cancer.[J]. Chin Med Sci J, 2011, 26(3):158-162. JIA Z Z, JIANG G M, FENG Y L. Serum HIF-1alpha and VEGF levels pre-and post-TACE in patients with primary liver cancer.[J]. Chin Med Sci J, 2011, 26(3):158-162.
6、 CARDIN R. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness.[J]. Am J Gastroenterol, 2008, 103(4):914-921. CARDIN R. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness.[J]. Am J Gastroenterol, 2008, 103(4):914-921.
7、 高潺潺,吴平平,金潇潇.VEGF、EGFR在原发性肝癌中的表达及其临床意义[J]. 南京医科大学学报(自然科学版),2016,36(12):1436-1439. 高潺潺,吴平平,金潇潇.VEGF、EGFR在原发性肝癌中的表达及其临床意义[J]. 南京医科大学学报(自然科学版),2016,36(12):1436-1439.
8、 KONG Y, SUN L, HOU Z, et al. Apatinib is effective for treatment of advanced hepatocellular carcinoma:[J]. Oncotarget, 2017, 8(62):105596-105605. KONG Y, SUN L, HOU Z, et al. Apatinib is effective for treatment of advanced hepatocellular carcinoma:[J]. Oncotarget, 2017, 8(62):105596-105605.
9、 QIN S K. Apatinib in Chinese patients with advanced hepatocellular carcinoma: a phaseⅡ randomized, open-label trial[J]. J Clin Oncol,2014, 32(15):17-20. QIN S K. Apatinib in Chinese patients with advanced hepatocellular carcinoma: a phaseⅡ randomized, open-label trial[J]. J Clin Oncol,2014, 32(15):17-20.
10、 SUN H, ZHU M S, WU W R, et al. Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: the jury is still out[J]. World J Hepatol, 2014, 6(12):830-835. SUN H, ZHU M S, WU W R, et al. Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: the jury is still out[J]. World J Hepatol, 2014, 6(12):830-835.
11、 BAO Y, FENG W M, TANG C W, et al. Endostatin inhibits angiogenesis in hepatocellular carcinoma after transarterial chemoembolization[J]. Hepatogastroenterol, 2012, 59(117):1566-1568. BAO Y, FENG W M, TANG C W, et al. Endostatin inhibits angiogenesis in hepatocellular carcinoma after transarterial chemoembolization[J]. Hepatogastroenterol, 2012, 59(117):1566-1568.
12、 WANG Y X, de BAERE T, IDEE J M, et al. Transcatheter embolization therapy in liver cancer: an update of clinical evidences[J]. Chin J Cancer Res,2015,27(2):96-121. WANG Y X, de BAERE T, IDEE J M, et al. Transcatheter embolization therapy in liver cancer: an update of clinical evidences[J]. Chin J Cancer Res,2015,27(2):96-121.
